Clinical pharmacist participation in selecting and dosing targeted drugs for a patient with ALK-positive non-small cell lung cancer: a case report

Ceritinib and alectinib are recommended as the second-line therapies in the 2019 Chinese Society of Clinical Oncology (CSCO) guidelines for patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) in whom the first-line therapy has failed, but no optimal second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Caifu, Liu, Tao, Liang, Weiting, Feng, Shiyin, Su, Zhiqiang, Tang, Hongmei, Huang, Hongbing, Chen, Zhuojia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506779/
https://www.ncbi.nlm.nih.gov/pubmed/34734040
http://dx.doi.org/10.21037/atm-21-3853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506779/
https://www.ncbi.nlm.nih.gov/pubmed/34734040
http://dx.doi.org/10.21037/atm-21-3853

Ejemplares similares